Programmed death-ligand 1

Programmed death-ligand 1
Name	Programmed death-ligand 1
Organism	Human
Uniprot	Q9NZQ7
Location	Plasma membrane

Programmed death-ligand 1 is an immune-regulatory transmembrane protein encoded by the CD274 gene that participates in inhibitory signaling to modulate adaptive immunity. It is widely studied across oncology, immunology, and infectious disease research and has been a focal point in translational medicine and pharmaceutical development. Major research efforts have linked its expression patterns to outcomes in clinical oncology and to therapeutic strategies pioneered in industry and academic centers.

Structure and expression

The protein exhibits a type I membrane topology with an extracellular immunoglobulin V-like domain and an immunoglobulin C-like domain similar to other members of the B7 family, features characterized in structural biology studies at institutions such as Harvard University, Stanford University, and Max Planck Society. Glycosylation sites mapped by researchers at Massachusetts Institute of Technology and University of Cambridge contribute to molecular weight heterogeneity observed in proteomics datasets generated at Broad Institute and European Molecular Biology Laboratory. CD274 transcriptional regulation and promoter architecture have been profiled by consortia including ENCODE Project and The Cancer Genome Atlas; expression is inducible by cytokines studied at National Institutes of Health and is constitutively expressed in certain tissues profiled by teams at Dana-Farber Cancer Institute and Johns Hopkins University. Cellular localization has been validated by microscopy groups at University of California, San Francisco and Cold Spring Harbor Laboratory across dendritic cells, macrophages, epithelial cells, and tumor-infiltrating leukocytes reported in cohorts from Memorial Sloan Kettering Cancer Center and Mayo Clinic.

Function and signaling

Engagement of the ligand with its receptor initiates inhibitory signaling cascades that modulate T cell receptor–driven activation, a mechanism dissected by laboratories at Salk Institute, Karolinska Institutet, and Weizmann Institute of Science. Downstream events intersect with kinases and phosphatases characterized in signaling work at University of Oxford and Yale University, affecting transcription factors studied at University of Chicago and University College London. Functional assays developed at Imperial College London and University of Toronto demonstrate suppression of cytotoxic responses, alteration of cytokine profiles, and modulation of metabolic pathways described by groups at Rockefeller University and Columbia University. Cross-talk with costimulatory and coinhibitory receptors has been explored in collaborative projects involving European Commission funding and networks including Howard Hughes Medical Institute investigators.

Role in cancer and immune evasion

Upregulation of the ligand on tumor cells and stromal elements has been documented in malignancies analyzed by multicenter trials at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Fred Hutchinson Cancer Research Center; tumor types include studies from Dana-Farber Cancer Institute cohorts on melanoma, lung, renal, and head and neck cancers. Mechanistic oncology research at UCLA, University of Pennsylvania, and Sloan Kettering Institute links expression to microenvironmental factors such as hypoxia described by teams at National Cancer Institute and to oncogenic signaling pathways elucidated by groups at Cold Spring Harbor Laboratory. Immune evasion phenotypes have been correlated with clinical series from Karolinska University Hospital and genomic analyses by Wellcome Sanger Institute, implicating tumor-intrinsic and host-driven processes investigated in international clinical networks including International Agency for Research on Cancer.

Diagnostic and prognostic significance

Immunohistochemistry and RNA-based assays standardized through collaborations between College of American Pathologists and industry partners at Roche and AbbVie are used to assess expression for diagnostic stratification, with scoring systems validated in trials coordinated by European Society for Medical Oncology and American Society of Clinical Oncology. Prognostic associations have been reported in meta-analyses led by investigators at Johns Hopkins University and University of Toronto linking expression levels to survival endpoints in cohorts from Mayo Clinic and Mount Sinai Health System. Companion diagnostic approvals emerged from regulatory reviews at Food and Drug Administration and European Medicines Agency guided by clinical trial evidence from consortia including National Comprehensive Cancer Network members.

Therapeutic targeting and inhibitors

Checkpoint blockade strategies targeting the receptor–ligand axis revolutionized oncology after clinical trials conducted at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and industry trials by Bristol-Myers Squibb, Merck & Co., Inc., and AstraZeneca. Monoclonal antibodies developed and assessed in phase I–III trials at National Cancer Institute and academic centers include agents that have received approvals following submissions to Food and Drug Administration and European Medicines Agency. Combination regimens and resistance mechanisms have been investigated in consortium studies supported by Bill & Melinda Gates Foundation and translational research at Fred Hutchinson Cancer Research Center; small-molecule and biologic modulators are under development at academic spinouts from Imperial College London and ETH Zurich.

Regulation and genetic variation

Transcriptional and post-transcriptional regulation has been characterized by groups at ENCODE Project, Broad Institute, and Cold Spring Harbor Laboratory, including influence from inflammatory mediators studied at National Institutes of Health and viral infections analyzed by teams at Centers for Disease Control and Prevention and Pasteur Institute. Single-nucleotide variants, copy-number alterations, and epigenetic modifications cataloged by The Cancer Genome Atlas and 1000 Genomes Project correlate with expression differences reported in population studies at Wellcome Trust–funded centers and in cancer genomics programs at Wellcome Sanger Institute. Germline and somatic alterations influencing therapeutic response have been mapped in translational cohorts coordinated by Alliance for Clinical Trials in Oncology and networks such as European Genome-phenome Archive.

Category:Immune system proteins